AIHC Capital
VC Fund
AIHC Capital is a VC fund focused on Biotechnology and Pharmaceutical. AIHC Capital
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries AIHC Capital invests in
Stages AIHC Capital invests in
Countries AIHC Capital invests in
Investment Focus
Industry
- Biotechnology 4 (100%)
- Pharmaceutical 2 (50%)
- Oncology 1 (25%)
- Biopharma 1 (25%)
- Health Care 1 (25%)
Stage
- Series B 3 (75%)
- Seed 1 (25%)
Country
- China 2 (50%)
- United States 2 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ArriVent
|
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. | $155M / Series B / Dec 29, 2022 | |
InxMed
|
InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equippedwith global-level top-notch know-how and efficient execution capabilities. | $50M / Series B / Mar 03, 2022 | |
OnCusp Therapeutics
|
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancerpatients around the world.It is founded by Bing Yuan, Eric Slosberg, and Andy Fu. | $25M / Seed / Apr 01, 2021 | |
LakeShore Biopharma
|
Yisheng Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection. | $130M / Series B / Feb 24, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does AIHC Capital invest in?
AIHC Capital invests primarily in Biotechnology, Pharmaceutical and Oncology startups, most often at Series B and Seed stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did AIHC Capital last invest?
The most recent investment recorded for AIHC Capital closed in Dec 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
